Loading stock data…
VKTX
$30.00-1.18 (-3.78%)
Market ClosedLast close May 1
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Viking Therapeutics, Inc. in the Healthcare sector is trading at $30.00. The stock is currently 30% below its 52-week high of $43.15, remaining 8.4% below its 200-day moving average. Technical signals show oversold RSI of 19 and bearish MACD signal, explaining why VKTX maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 19) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$30.00
Potential Upside
5%
Whystock Fair Value$31.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus18 analysts
Mean target$92.33+207.8%
Range$34.00 – $125.00
Fundamentals
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.84%
Volume
Today's trading volume
2.88M
Recent News
Why Viking Therapeutics (VKTX) Is Down 8.4% After Expanding VK2735 Phase 3 Obesity Program And Loss
In late April 2026, Viking Therapeutics reported a wider first‑quarter net loss of US$158.33 million as research and development spending accelerated, while confirming that its Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials for VK2735 are now fully enrolled. Beyond the larger loss, the company’s move to expand VK2735 into both injectable and planned oral Phase 3 programs, alongside an IND filing for new amylin candidate VK3019 and preparation for commercialization, highlights an intensive...
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs
Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.
Viking Therapeutics Inc (VKTX) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid ...
Viking Therapeutics Inc (VKTX) reports increased R&D expenses and net loss, while making significant progress in clinical trials and maintaining a strong cash position.
Viking Therapeutics Q1 Earnings Call Highlights
Viking Therapeutics (NASDAQ:VKTX) reported first-quarter 2026 financial results and outlined progress across its obesity pipeline during an earnings call held April 29, 2026. Management emphasized rapid advancement of its dual GLP-1/GIP agonist VK2735 in both injectable and oral formulations, expans
What is Driving a Strong Bullish Sentiment Towards Viking Therapeutics (VKTX)
Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 best biotech stocks with highest upside potential. Back on March 26, Viking Therapeutics Inc. (NASDAQ:VKTX) reported the final recruitment of patients into the Phase 3 VANQUISH-2 study of its investigational subcutaneous drug VK2735, a dual agonist of the GLP-1 and GIP receptors. The drug is being […]